Tandem Diabetes Care (NASDAQ:TNDM) PT Raised to $40.00 at Stifel Nicolaus

Tandem Diabetes Care (NASDAQ:TNDM) had its target price hoisted by equities research analysts at Stifel Nicolaus from $37.00 to $40.00 in a research note issued to investors on Tuesday, Benzinga reports. The firm presently has a “buy” rating on the medical device company’s stock. Stifel Nicolaus’ price target would indicate a potential upside of 13.90% from the stock’s current price.

Other analysts have also recently issued reports about the company. Citigroup increased their price objective on Tandem Diabetes Care from $31.00 to $38.00 and gave the company a “neutral” rating in a research note on Wednesday, April 3rd. StockNews.com upgraded Tandem Diabetes Care from a “sell” rating to a “hold” rating in a research note on Friday, April 19th. One investment analyst has rated the stock with a sell rating, six have given a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $37.27.

Tandem Diabetes Care Price Performance

TNDM stock opened at $35.12 on Tuesday. The firm has a market capitalization of $2.27 billion, a PE ratio of -10.21 and a beta of 1.12. Tandem Diabetes Care has a 1 year low of $13.82 and a 1 year high of $40.74. The company has a debt-to-equity ratio of 0.91, a current ratio of 3.83 and a quick ratio of 3.02. The business has a 50 day simple moving average of $30.51 and a 200-day simple moving average of $25.18.

Tandem Diabetes Care (NASDAQ:TNDM) last issued its quarterly earnings data on Wednesday, February 21st. The medical device company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.04). The business had revenue of $196.80 million during the quarter, compared to analysts’ expectations of $204.86 million. Tandem Diabetes Care had a negative return on equity of 31.48% and a negative net margin of 29.77%. Equities research analysts anticipate that Tandem Diabetes Care will post -1.62 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Tandem Diabetes Care

A number of large investors have recently added to or reduced their stakes in the business. MCF Advisors LLC grew its stake in Tandem Diabetes Care by 79.3% in the 1st quarter. MCF Advisors LLC now owns 1,006 shares of the medical device company’s stock valued at $36,000 after acquiring an additional 445 shares during the last quarter. Van ECK Associates Corp grew its stake in Tandem Diabetes Care by 8.6% in the 4th quarter. Van ECK Associates Corp now owns 5,900 shares of the medical device company’s stock valued at $175,000 after acquiring an additional 467 shares during the last quarter. Diversified Trust Co grew its stake in Tandem Diabetes Care by 5.6% in the 4th quarter. Diversified Trust Co now owns 10,573 shares of the medical device company’s stock valued at $313,000 after acquiring an additional 564 shares during the last quarter. Raymond James & Associates grew its stake in Tandem Diabetes Care by 1.9% in the 3rd quarter. Raymond James & Associates now owns 40,264 shares of the medical device company’s stock valued at $836,000 after acquiring an additional 737 shares during the last quarter. Finally, Commonwealth Equity Services LLC grew its stake in Tandem Diabetes Care by 10.1% in the 3rd quarter. Commonwealth Equity Services LLC now owns 9,870 shares of the medical device company’s stock valued at $205,000 after acquiring an additional 908 shares during the last quarter.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.